Endonovo Therapeutics, Inc.
ENDV
$0.0002
$0.000.00%
| Weiss Ratings | ENDV - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Unrated | |||
| Risk Index | Unrated | |||
| Risk Grade | U | |||
| Reward Grade | U | |||
| Rating Factors | ENDV - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | Unrated | |||
| Growth Index | Unrated | |||
| Efficiency Index | Unrated | |||
| Solvency Index | Unrated | |||
| Total Return Index | Unrated | |||
| Volatility Index | Unrated | |||
| Beta / Standard Deviation | ENDV - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -0.94 | |||
| Price History | ENDV - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -33.33% | |||
| 30-Day Total Return | -33.33% | |||
| 60-Day Total Return | -50.00% | |||
| 90-Day Total Return | -80.00% | |||
| Year to Date Total Return | -71.43% | |||
| 1-Year Total Return | -92.31% | |||
| 2-Year Total Return | -98.97% | |||
| 3-Year Total Return | -98.94% | |||
| 5-Year Total Return | -99.85% | |||
| 52-Week High % Change | -94.44% | |||
| 52-Week Low % Change | 100.00% | |||
| Price | ENDV - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.00 | |||
| 52-Week Low Price | $0.00 | |||
| 52-Week Low Price (Date) | Feb 13, 2025 | |||
| 52-Week High Price (Date) | Apr 10, 2024 | |||
| Valuation | ENDV - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 170.74K | |||
| Enterprise Value | 7.23M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.07 | |||
| Earnings Per Share Growth | 230.28% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.25 | |||
| Price/Book (Q) | 0.00 | |||
| Enterprise Value/Revenue (TTM) | 28.27 | |||
| Price | $0.00 | |||
| Enterprise Value/EBITDA (TTM) | -3.67 | |||
| Enterprise Value/EBIT | -2.76 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | ENDV - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 298.39M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ENDV - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 800 489 4774 | |||
| Address | 6320 Canoga Avenue Woodland Hills, CA 91367 | |||
| Website | www.endonovo.com | |||
| Country | United States | |||
| Year Founded | 2008 | |||
| Profitability | ENDV - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -1,023.26% | |||
| Profit Margin | -1,722.36% | |||
| Management Effectiveness | ENDV - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -144.26% | |||
| Return on Equity | -- | |||
| Income Statement | ENDV - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 255.70K | |||
| Total Revenue (TTM) | 255.70K | |||
| Revenue Per Share | $0.00 | |||
| Gross Profit (TTM) | 246.00K | |||
| EBITDA (TTM) | -1.97M | |||
| EBIT (TTM) | -2.62M | |||
| Net Income (TTM) | -4.40M | |||
| Net Income Avl. to Common (TTM) | -4.40M | |||
| Total Revenue Growth (Q YOY) | -86.36% | |||
| Earnings Growth (Q YOY) | -26.98% | |||
| EPS Diluted (TTM) | -0.07 | |||
| EPS Diluted Growth (Q YOY) | 33.33% | |||
| Balance Sheet | ENDV - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | -- | |||
| Cash Per Share (Q) | -- | |||
| Total Current Assets (Q) | 35.50K | |||
| Total Preferred Equity (Q) | 0.00 | |||
| Total Equity (Q) | -22.96M | |||
| Current Ratio (Q) | 0.001 | |||
| Book Value Per Share (Q) | -$0.07 | |||
| Total Assets (Q) | 815.80K | |||
| Total Current Liabilities (Q) | 23.70M | |||
| Total Debt (Q) | 7.06M | |||
| Total Liabilities (Q) | 23.78M | |||
| Total Common Equity (Q) | -22.96M | |||
| Cash Flow | ENDV - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -- | |||
| Cash from Financing (TTM) | 606.80K | |||
| Net Change in Cash (TTM) | -23.10K | |||
| Levered Free Cash Flow (TTM) | 1.28M | |||
| Cash from Operations (TTM) | -629.90K | |||
